StemCells, Inc. to Participate at the 2015 Marcum MicroCap Conference
May 18 2015 - 7:05AM
StemCells, Inc. (Nasdaq:STEM) announced today that management will
make a presentation on the Company's programs, pipeline and
operations at the 2015 Marcum MicroCap Conference. Management is
scheduled to speak at 1:30 p.m. Eastern Daylight Time on Thursday,
May 28, at The Grand Hyatt New York Hotel, in the Imperial room,
located at 109 E 42nd Street in New York City.
A live webcast of the presentation will be available through the
Company's corporate website: http://www.stemcellsinc.com.
Interested parties are encouraged to connect to the website at
least 15 minutes prior to the presentation to ensure adequate time
for any software downloads that may be necessary. In addition, you
may directly access the webcast through the following link:
http://wsw.com/webcast/marcum3/stem. A replay will also be
accessible for 90 days through the Company's website.
About the Marcum MicroCap Conference
The Marcum MicroCap Conference is dedicated to providing a forum
where publicly traded companies under $500 million in market
capitalization can network with the investment community. The
conference features presentations by CEOs and CFOs from six
principal industry sectors and provides investors with the
opportunity to meet with management of these companies on a
one-on-one basis. Industry sectors include Technology, Media
& Internet; Software & Business Services; Life Science
& Healthcare; Retail & Consumer Products; Energy &
Natural Resources; and Industrials. The conference additionally
includes a full agenda of panel discussions on issues of strategic
importance to small cap issuers and investors, moderated by
industry leaders.
The Marcum MicroCap Conference attracts fund managers and high
net worth investors focusing on small cap equities. Over 2,000
participants from all segments of the microcap market attend each
year, including senior management, finance and legal
executives, venture and lower middle-market private equity
investors, institutional investors, directors, investment bankers,
buy- and sell-side analysts, and service providers to the microcap
marketplace.
For complete information about the 2015 Marcum MicroCap
Conference, visit www.marcumllp.com/microcap.
About StemCells, Inc.
StemCells, Inc. is currently engaged in clinical development of
its platform technology, HuCNS-SC® (purified human neural stem
cells) as a potential treatment for disorders of the central
nervous system (CNS). Top line data from the Company's Phase I/II
clinical trial in thoracic spinal cord injury (SCI) showed
measurable gains involving multiple sensory modalities and
segments, including the conversion of 2 of 7 patients enrolled in
the study with complete injuries (AIS A) converting to incomplete
injuries (AIS B), post-transplant. In addition to the completion of
the Phase I/II thoracic SCI study and the ongoing Phase II
PathwayTM study for cervical spinal cord injuries, StemCells, Inc.
has completed enrollment in its Phase I/II clinical trial in
geographic atrophy of age-related macular degeneration (GA-AMD),
the most severe form of dry AMD and the leading cause of blindness
in the elderly. Based upon interim results for patients who had
completed twelve months of follow-up, the Company reported
reductions in the rate of progression in GA as compared to the
untreated eye and the expected natural history of the disease. In a
Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD),
a fatal myelination disorder in children, the Company showed
preliminary evidence of progressive and durable donor-derived
myelination by MRI. Further information about StemCells, Inc.
is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press
release constitutes forward-looking statements within the meaning
of the U.S. securities laws, and is subject to the safe harbors
created therein. These forward-looking statements speak only as of
the date of this news release. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks and
uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31,
2014 and in its subsequent reports on Forms 10-Q and 8-K.
CONTACT: Greg Schiffman
StemCells, Inc.
Chief Financial Officer
(510) 456-4128
Lena Evans
Russo Partners
(212) 845-4262
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2024 to May 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From May 2023 to May 2024